Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 10000 participants.
Also called NCT01924325
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 10,000 participants
- Sponsor
- Registry
-
NCT01924325
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT01924325. Randomized; triple masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2015-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events
- Acronym
- ADANCE
- Condition
- Ischemic Stroke
- Condition
- TIA (transient ischemic attack)
- Intervention (Drug)
- Apixaban
- Intervention (Drug)
- Clopidogrel
- Intervention (Drug)
- Aspirin
- Intervention (Drug)
- placebo
- Lead sponsor
- Xijing Hospital
Record details
- Record id
cardio:ct-nct01924325- Content hash
fb266168078ffd3bfeb30452224425656889fc2b5066bc01c42cd7ccdbd75f5a